About
Technology
Issues
FAQ
Links
Official Page
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.